Clinical Research On Therapy Of Renal-Vi Tal-Reinforce And Bone-Vital-Strong Prescription In Treating Postmenopausal Osteoporosis With Deficiency Of Liver-Yin And Kidney-Yin

Purpose:To discuss the understanding of traditional Chinese medicine about postmenopausal osteoporosis, using the therapy of renal-vital-reinforce and Bone-vital-strong Prescription to treat postmenopausal osteoporosis.To observe the therapeutic efficacy of this prescription in treating postmenopausal osteoporosis with deficiency of liver-yin and kidney-yin symptoms by the indexes such as clinical symptom, bone mineral density(BMD), serum calcium and phosphorus, estradiol, testoterone, interleukin-6(IL-6).Then evaluating its safety, so as to guide its clinical application.Methods:A randomized, controlled trial was conducted.The patients of postmenopausal osteoporosis were randomly classified into two groups.On the basic of normal treatment and western medicine, the patients of treated group were treated by Chinese medicine while the patients of controlled group were treated by Alfacalcidol Capsule and Caltrate Vitamin D3Tabletas.,which was observed for3month and four weeks were a course of treatment..The observed indexes included curative effect indexes, such as clinic symptoms, bone mineral density, serum calcium and phosphorus, estradiol, testoterone, interleukin-6and so on. The complete data carries on statistics analysis by the SPSS16.0statistics software.Results:The diagnosis and included postmenopausal osteoporosis patients with50cases.25cases of treated group,while25cases of controlled group.Prior treatment,age,course of disease of the two groups patients had no differeces.1.Symptoms and signs improvement:the treated group after treatment had a significant improvement. The symptoms improvement of the treated group was better than the controlled group (P<0.05).2. Bone mineral density:After treatment, the BMD of the treated group were significantly higher than controlled group(P<0.01) while the controlled group had no statistical significance(P>0.05).The BMD of the treated group had a difference than controlled group(P<0.05).3. Serum calcium and phosphate:Serum calcium of the two groups were higher, but had no statistical significance(P>0.05).Serum phosphate of the two groups were lower, but had no statistical significance.Serum calcium and phosphate of the controlled group had no statistical significance(P>0.05).4.Hormone:after treatment, the E2of the treated group was visibly higher(P<0.01) while the T was visibly lower(P<0.01).The improvement of E2of the treated group was better than the controlled group(P＜0.01) and the improvement of T of the treated group was better than the controlled group, and had a statistical significance(P<0.05).5.IL-6:After treatment, the IL-6of the treated group were also significantly improved(P＜0.01), and had a significantly difference than controlled group(P<0.01).6.Safety index:The routine blood/urine/feces test, and the liver and kidney function tests of treated group were within the normal range. Two groups had no unhealthy response.Conclusion:Through the preliminary clinical study,chinese medicine of method has sure curative effected in treating postmenopausal osteoporosis with deficiency of liver-yin and kidney-yin.From the angle of western medicine,it is safe and can improve BMD,adjust hormone,and has no side-effect of liver and kidney. It is worth studying deeply and developing further.